Lindgren Eva M, Nielsen Ronni, Petrovic Natasa, Jacobsson Anders, Mandrup Susanne, Cannon Barbara, Nedergaard Jan
The Wenner-Gren Institute, The Arrhenius Laboratories F3, Stockholm University, SE-106 91 Stockholm, Sweden.
Biochem J. 2004 Sep 1;382(Pt 2):597-606. doi: 10.1042/BJ20031622.
PPAR (peroxisome-proliferator-activated receptor) gamma is expressed in brown and white adipose tissues and is involved in the control of differentiation and proliferation. Noradrenaline stimulates brown pre-adipocyte proliferation and brown adipocyte differentiation. The aim of the present study was thus to investigate the influence of noradrenaline on PPARgamma gene expression in brown adipocytes. In primary cultures of brown adipocytes, PPARgamma2 mRNA levels were 20-fold higher than PPARgamma1 mRNA levels. PPARgamma expression occurred during both the proliferation and the differentiation phases, with the highest mRNA levels being found at the time of transition between the phases. PPARgamma2 mRNA levels were downregulated by noradrenaline treatment (EC50, 0.1 microM) in both proliferative and differentiating cells, with a lagtime of 1 h and lasting up to 4 h, after which expression gradually recovered. The down-regulation was beta-adrenoceptor-induced and intracellularly mediated via cAMP and protein kinase A; the signalling pathway did not involve phosphoinositide 3-kinase, Src, p38 mitogen-activated protein kinase or extracellular-signal-regulated kinases 1 and 2. Treatment of the cells with the protein synthesis inhibitor cycloheximide not only abolished the noradrenaline-induced down-regulation of PPARgamma2 mRNA, but also in itself induced PPARgamma2 hyperexpression. The down-regulation was probably the result of suppression of transcription. The down-regulation of PPARgamma2 mRNA resulted in similar down-regulation of PPARgamma2 and phosphoPPARgamma2 protein levels. Remarkably, the level of PPARgamma1 protein was similar to that of PPARgamma2 (despite almost no PPARgamma1 mRNA), and the down-regulation by noradrenaline demonstrated similar kinetics to that of PPARgamma2; thus PPARgamma1 was apparently translated from the PPARgamma2 template. It is suggested that beta-adrenergic stimulation via cAMP and protein kinase A represses PPARgamma gene expression, leading to reduction of PPARgamma2 mRNA levels, which is then reflected in down-regulated levels of PPARgamma2, phosphoPPARgamma2 and PPARgamma1.
过氧化物酶体增殖物激活受体(PPAR)γ在棕色和白色脂肪组织中表达,参与细胞分化和增殖的调控。去甲肾上腺素可刺激棕色前脂肪细胞增殖和棕色脂肪细胞分化。因此,本研究旨在探讨去甲肾上腺素对棕色脂肪细胞中PPARγ基因表达的影响。在棕色脂肪细胞原代培养中,PPARγ2 mRNA水平比PPARγ1 mRNA水平高20倍。PPARγ在增殖期和分化期均有表达,在两个阶段转换时mRNA水平最高。在增殖细胞和分化细胞中,去甲肾上腺素处理(EC50,0.1微摩尔)均可下调PPARγ2 mRNA水平,滞后时间为1小时,持续长达4小时,之后表达逐渐恢复。这种下调是由β-肾上腺素能受体诱导的,通过细胞内的cAMP和蛋白激酶A介导;信号通路不涉及磷脂酰肌醇3激酶、Src、p38丝裂原活化蛋白激酶或细胞外信号调节激酶1和2。用蛋白质合成抑制剂环己酰亚胺处理细胞,不仅消除了去甲肾上腺素诱导的PPARγ2 mRNA下调,而且其本身还诱导了PPARγ2的过表达。这种下调可能是转录抑制的结果。PPARγ2 mRNA的下调导致PPARγ2和磷酸化PPARγ2蛋白水平出现类似下调。值得注意的是,PPARγ1蛋白水平与PPARγ2相似(尽管几乎没有PPARγ1 mRNA),而去甲肾上腺素引起的下调与PPARγ2表现出相似的动力学;因此,PPARγ1显然是从PPARγ2模板翻译而来的。提示通过cAMP和蛋白激酶A的β-肾上腺素能刺激可抑制PPARγ基因表达,导致PPARγ2 mRNA水平降低,进而反映在PPARγ2、磷酸化PPARγ2和PPARγ1水平的下调上。